Homology Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Homology Medicines, a clinical-stage genetic medicines company, will participate in two virtual conferences: the BTIG Virtual Biotechnology Conference on August 9 at 1:30 p.m. ET and the Canaccord Genuity 41st Annual Growth Conference on August 11 at 9:00 a.m. ET. The Canaccord presentation will be available for 90 days on their website. Homology focuses on treating rare diseases through gene therapy, including programs for phenylketonuria and lysosomal storage disorders. Their innovative AAVHSC platform enables efficient genetic medicine delivery.

BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences:

• BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m. ET
• Canaccord Genuity 41st Annual Growth Conference: August 11 at 9:00 a.m. ET

The webcast presentation from the Canaccord conference will be accessible on Homology’s website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation.

About Homology Medicines, Inc.
Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by targeting the underlying cause of the disease. The Company’s lead clinical program, HMI-102, is a gene therapy for adults with phenylketonuria (PKU) and additional programs focus on lysosomal storage disorders including Hunter syndrome, paroxysmal nocturnal hemoglobinuria (PNH) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases and believes that its data, internal manufacturing capabilities and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.

Company Contacts
Theresa McNeely
Chief Communications Officer
and Patient Advocate
tmcneely@homologymedicines.com
781-301-7277

Media Contact:
Cara Mayfield
Vice President, Patient Advocacy
and Corporate Communications
cmayfield@homologymedicines.com
781-691-3510

FAQ

What is the schedule for Homology Medicines' upcoming virtual conferences in August 2021?

Homology Medicines will participate in the BTIG Virtual Biotechnology Conference on August 9 at 1:30 p.m. ET and the Canaccord Genuity 41st Annual Growth Conference on August 11 at 9:00 a.m. ET.

How can I access the webcast from Homology Medicines' conference presentation?

The webcast from the Canaccord Genuity conference will be accessible on Homology's website in the Investors section and will be available for 90 days after the presentation.

What diseases does Homology Medicines focus on treating?

Homology Medicines focuses on treating rare diseases, particularly through gene therapy for conditions like phenylketonuria and lysosomal storage disorders.

What is the significance of Homology Medicines' AAVHSC platform?

Homology's AAVHSC platform allows for precise and efficient delivery of genetic medicines, enhancing their gene therapy and editing capabilities.

What is Homology Medicines' lead clinical program?

Homology Medicines' lead clinical program is HMI-102, a gene therapy aimed at treating adults with phenylketonuria (PKU).